Jyoti Srivastava

Jyoti Srivastava

Auto-generated profile, based on publicly available information

Jyoti Srivastava

Department of Tumor Microenvironment and Metastasis H. Lee Moffitt Cancer Center and Research Institute Tampa Florida USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2025 in Cancer Research
Verified
Journal Article
Open access
JSJyoti Srivastava
Jyoti Srivastava
VYVipin Kumar Yadav
Vipin Kumar Yadav
RJRachel V. Jimenez
Rachel V. Jimenez
PPPravin R. Phadatare
Pravin R. Phadatare
NINinad A. Inamdar
Ninad A. Inamdar
SPSanjay Premi
Sanjay Premi
Activating NRAS mutations occur in 15% to 25% of all melanomas. However, this subtype remains refractory to existing therapeutics, including immunotherapy and RAS inhibitors; therefore, identifying innovative treatment strategies is of utmost importance. We investigated the role of nitrosylation, a nitric oxide–induced posttranslational modification, in melanoma progression and therapeutic resistance. Inhibiting nitrosylation sensitized NRAS-mutant melanomas to targeted MEK inhibitors (MEKi), leading to sustained downregulation of the ERK-MAPK pathway, along with concomitant denitrosylation of NRAS, MEK, ERK, RSK1, and DUSPs. Global nitrosylome profiling using mass spectrometry revealed nitrosylation of multiple ERK regulators. Gain- and loss-of-function studies confirmed a positive association between nitrosylation and ERK activation. ERK and MEK proteins harbored potential nitrosylation sites, mutation of which abrogated their phosphorylation and inhibited cell growth. The nitrosylome also contained damage-associated molecular patterns (DAMP), factors known to induce immunogenic cell death (ICD). Notably, nitrosylation inhibition combined with MEKi markedly inhibited NRAS-mutant melanoma growth in an immunocompetent mouse model. This was accompanied by downregulated MEK-ERK signaling and extracellular release of DAMPs such as calreticulin, phospho-eIF2α, and HMGB1, confirming ICD induction. Furthermore, the combination significantly increased the repertoire of CD8+ T cells, dendritic cells, and macrophages in the tumor microenvironment, which was validated in cocultures of dendritic cells and T lymphocytes. In conclusion, the current study demonstrates that nitrosylation inhibition sensitizes NRAS-mutant melanomas to targeted MEKi-induced cell death and causes the release of non-nitrosylated (active) DAMPs that induce a potent antimelanoma immune response via ICD. These findings highlight potential therapeutic vulnerabilities in the currently untreatable NRAS-mutant melanoma subtype. Significance: Nitrosylation-regulated molecular mechanisms present a vulnerability that can be exploited to sensitize NRAS-mutant melanomas to existing targeted therapies while enhancing antitumor immunity.

16 June 2025
Verified
Other
Open access
JSJyoti Srivastava
Jyoti Srivastava
VYVipin Kumar Yadav
Vipin Kumar Yadav
RJRachel V. Jimenez
Rachel V. Jimenez
PPPravin R. Phadatare
Pravin R. Phadatare
NINinad A. Inamdar
Ninad A. Inamdar
SPSanjay Premi
Sanjay Premi
Legends for Supplementary Figures and Supplementary Tables.

23 September 2026 in Photochemistry and Photobiology
Verified
Journal Article
Open access
PDF file
JSJyoti Srivastava
Jyoti Srivastava
MCMarcus Cooke
Marcus Cooke
SPSanjay Premi
Sanjay Premi
The action spectrum of cyclobutane pyrimidine dimer (CPD) formation has long been viewed as reflecting the DNA absorption spectrum and closely aligned with the erythema (sunburn) spectrum. This alignment established the prevailing paradigm in which erythema serves as a surrogate for mutagenic risk and ultraviolet B radiation (UVB) is responsible for biologically meaningful DNA damage in skin. However, the discovery of delayed or “dark” CPDs, generated through post‐exposure biochemical processes such as melanin‐dependent chemiexcitation, extends and refines this classical view. It is increasingly well established that CPD formation is not limited to direct photon absorption but can additionally arise through longer‐wavelength, redox‐driven chemiexcitation pathways, particularly within the UVA range. Emerging evidence further suggests that non‐melanin oxidative pathways, including lipid peroxidation, can generate chemiexcited states potentially relevant to DNA damage. In light of this evidence, we propose that the biological action spectrum for CPD formation is determined not only by direct DNA absorption, but also by the capacity of cells to generate DNA damaging excited states through redox chemistry. This novel framework reshapes how light exposure is linked to mutagenesis and underscores the need for next‐generation photoprotective strategies targeting both direct and indirect DNA damage pathways.

16 June 2025
Verified
Other
Open access
JSJyoti Srivastava
Jyoti Srivastava
VYVipin Kumar Yadav
Vipin Kumar Yadav
RJRachel V. Jimenez
Rachel V. Jimenez
PPPravin R. Phadatare
Pravin R. Phadatare
NINinad A. Inamdar
Ninad A. Inamdar
SPSanjay Premi
Sanjay Premi
Activating NRAS mutations occur in 15% to 25% of all melanomas. However, this subtype remains refractory to existing therapeutics, including immunotherapy and RAS inhibitors; therefore, identifying innovative treatment strategies is of utmost importance. We investigated the role of nitrosylation, a nitric oxide–induced posttranslational modification, in melanoma progression and therapeutic resistance. Inhibiting nitrosylation sensitized NRAS-mutant melanomas to targeted MEK inhibitors (MEKi), leading to sustained downregulation of the ERK-MAPK pathway, along with concomitant denitrosylation of NRAS, MEK, ERK, RSK1, and DUSPs. Global nitrosylome profiling using mass spectrometry revealed nitrosylation of multiple ERK regulators. Gain- and loss-of-function studies confirmed a positive association between nitrosylation and ERK activation. ERK and MEK proteins harbored potential nitrosylation sites, mutation of which abrogated their phosphorylation and inhibited cell growth. The nitrosylome also contained damage-associated molecular patterns (DAMP), factors known to induce immunogenic cell death (ICD). Notably, nitrosylation inhibition combined with MEKi markedly inhibited NRAS-mutant melanoma growth in an immunocompetent mouse model. This was accompanied by downregulated MEK-ERK signaling and extracellular release of DAMPs such as calreticulin, phospho-eIF2α, and HMGB1, confirming ICD induction. Furthermore, the combination significantly increased the repertoire of CD8+ T cells, dendritic cells, and macrophages in the tumor microenvironment, which was validated in cocultures of dendritic cells and T lymphocytes. In conclusion, the current study demonstrates that nitrosylation inhibition sensitizes NRAS-mutant melanomas to targeted MEKi-induced cell death and causes the release of non-nitrosylated (active) DAMPs that induce a potent antimelanoma immune response via ICD. These findings highlight potential therapeutic vulnerabilities in the currently untreatable NRAS-mutant melanoma subtype.Significance:Nitrosylation-regulated molecular mechanisms present a vulnerability that can be exploited to sensitize NRAS-mutant melanomas to existing targeted therapies while enhancing antitumor immunity.


16 June 2025
Verified
Other
Open access
JSJyoti Srivastava
Jyoti Srivastava
VYVipin Kumar Yadav
Vipin Kumar Yadav
RJRachel V. Jimenez
Rachel V. Jimenez
PPPravin R. Phadatare
Pravin R. Phadatare
NINinad A. Inamdar
Ninad A. Inamdar
SPSanjay Premi
Sanjay Premi
Densitometric analyses of ERK and MEK mutants in the nitrosylomic and cellular fractions of HEK293 cells.